Sukoff Rizzo Stacey J, Schechter Lee E, Rosenzweig-Lipson Sharon
Depression and Anxiety Research, Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543-8000, USA.
Psychopharmacology (Berl). 2008 Jan;195(4):459-67. doi: 10.1007/s00213-007-0924-7. Epub 2007 Sep 16.
Sexual dysfunction is associated with antidepressant discontinuation. Therefore, there is a need for models that predict antidepressant-induced sexual dysfunction.
To develop a predictive method for evaluating antidepressant-induced sexual dysfunction.
Male Sprague-Dawley rats were allowed access to sexually receptive females during a single overnight mating session and then treated with antidepressants known to produce differing levels of sexual dysfunction in the clinic. Two to three weeks later, following either acute, subchronic (7-day), or chronic (14-day) antidepressant treatment, rats were observed for penile erections (PE) in the presence of sexually receptive females that were not accessible for contact but served as visual, auditory, and olfactory stimuli in the testing area.
Chronic treatment of fluoxetine (10 mg/kg), desipramine (10 mg/kg), and bupropion (20 mg/kg) reduced the number of PE 71, 53, and 8%, respectively, relative to vehicle-treated rats. This rank order of the compounds' propensity for reducing PE is comparable to the rank order of the compounds' ability to produce sexual dysfunction during antidepressant treatment in the clinic. Additionally, drugs used to treat antidepressant-induced sexual dysfunction in the clinic, such as sildenafil, yohimbine, and dopamine agonists, were also effective in attenuating the deficits in the number of noncontact PE produced by chronic fluoxetine treatment.
Taken together, this model represents a novel approach for predicting antidepressant-induced sexual dysfunction in rats, which parallels the pattern of reports of sexual dysfunction in the clinic associated with different antidepressant treatments and the ability of adjunct treatment to reverse the sexual impairments produced by antidepressants.
性功能障碍与停用抗抑郁药有关。因此,需要能够预测抗抑郁药引起的性功能障碍的模型。
开发一种评估抗抑郁药引起的性功能障碍的预测方法。
在单次过夜交配期间,让雄性斯普拉格-道利大鼠接触性接受的雌性大鼠,然后用已知在临床上会产生不同程度性功能障碍的抗抑郁药进行治疗。两到三周后,在急性、亚慢性(7天)或慢性(14天)抗抑郁药治疗后,观察大鼠在有性接受的雌性大鼠存在时的阴茎勃起(PE)情况,这些雌性大鼠不可接触,但在测试区域作为视觉、听觉和嗅觉刺激。
与用赋形剂处理的大鼠相比,慢性给予氟西汀(10mg/kg)、地昔帕明(10mg/kg)和安非他酮(20mg/kg)分别使PE次数减少了71%、53%和8%。这些化合物减少PE的倾向顺序与它们在临床上抗抑郁药治疗期间产生性功能障碍的能力顺序相当。此外,临床上用于治疗抗抑郁药引起的性功能障碍的药物,如西地那非、育亨宾和多巴胺激动剂,也能有效减轻慢性氟西汀治疗引起的非接触性PE次数的缺陷。
综上所述,该模型代表了一种预测大鼠抗抑郁药引起的性功能障碍的新方法,这与临床上与不同抗抑郁药治疗相关的性功能障碍报告模式以及辅助治疗逆转抗抑郁药引起的性功能损害的能力相似。